Evolus (EOLS) Non-Current Deferred Tax Liability (2017 - 2026)
Evolus (EOLS) posted Non-Current Deferred Tax Liability of $23000.0 for Q1 2026, down 17.86% on a QoQ basis from $28000.0 in Q4 2025, and up 1050.0% year-over-year from $2000.0 in Q1 2025.
Evolus (EOLS) Non-Current Deferred Tax Liability (2017 - 2026) Analysis & Trends
Evolus' Non-Current Deferred Tax Liability history runs 10 years deep, the most recent figure standing at $23000.0 for Q1 2026.
- Quarterly Non-Current Deferred Tax Liability rose 1050.0% year-over-year to $23000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23000.0 (up 1050.0% YoY) and the FY2025 annual result came in at $28000.0, up 366.67% from the prior year.
- Non-Current Deferred Tax Liability was $23000.0 for Q1 2026 at Evolus, down from $28000.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $32000.0 in Q1 2024 and bottomed at $2000.0 in Q1 2025.
- A 5-year average of $22625.0 and a median of $23000.0 in 2022 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2025 — Non-Current Deferred Tax Liability slumped 93.75% — and 2026, when it surged 1050.0%.
- Evolus' Non-Current Deferred Tax Liability stood at $22000.0 in 2022, then increased by 22.73% to $27000.0 in 2023, then sank by 77.78% to $6000.0 in 2024, then soared by 366.67% to $28000.0 in 2025, then slipped by 17.86% to $23000.0 in 2026.
- Business Quant data shows EOLS's Non-Current Deferred Tax Liability at $23000.0 in Q1 2026, $28000.0 in Q4 2025, and $21000.0 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Evolus | 390.47 Mn | 340.68 Mn | 48.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23,000.00 |
| Mar 31, 2026 | 23,000.00 |
| Dec 31, 2025 | 28,000.00 |
| Dec 31, 2025 | 28,000.00 |
| Jun 30, 2025 | 21,000.00 |
| Jun 30, 2025 | 21,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Sep 30, 2024 | 29,000.00 |
| Sep 30, 2024 | 29,000.00 |
| Jun 30, 2024 | 29,000.00 |
| Jun 30, 2024 | 29,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Dec 31, 2023 | 27,000.00 |
| Dec 31, 2023 | 27,000.00 |
| Sep 30, 2023 | 22,000.00 |
| Sep 30, 2023 | 22,000.00 |